The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
CA125 and Ovarian Cancer: A Comprehensive Review
Open accessAbstract
Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has been used as the primary ovarian cancer marker for the past four decades. The focus on diagnosing ovarian cancer in stages I and II using CA125 as a diagnostic biomarker has not improved patients’ survival. Therefore, screening average-risk asymptomatic women with CA125 is not recommended by any professional society. The dualistic model of ovarian cancer carcinogenesis suggests that type II tumours are responsible for the majority of ovarian cancer mortality. However, type II tumours are rarely diagnosed in stages I and II. The recent shift of focus to the diagnosis of low volume type II ovarian cancer in its early stages of evolution provides a new and valuable target for screening. Type II ovarian cancers are usually diagnosed in advanced stages and have significantly higher CA125 levels than type I tumours. The detection of low volume type II carcinomas in stage IIIa/b is associated with a higher likelihood for optimal cytoreduction, the most robust prognostic indicator for ovarian cancer patients. The diagnosis of type II ovarian cancer in the early substages of stage III with CA125 may be possible using a higher cutoff point rather than the traditionally used 35 U/mL through the use of point-of-care CA125 assays in primary care facilities. Rapid point-of-care testing also has the potential for effective longitudinal screening and quick monitoring of ovarian cancer patients during and after treatment. This review covers the role of CA125 in the diagnosis and management of ovarian cancer and explores novel and more effective screening strategies with CA125.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
HEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048 · cited 1×
“However, later post-hoc analysis showed a moderate increase in survival between years 7–14 of follow-up [31].”
MethodJACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814 · cited 1×
“HGSC and endometroid ovarian cancers have a higher expression of CA125 compared to other subtypes [48].”
BackgroundPiek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Structure and Function of the Cell Surface (Tethered) Mucins
Hattrup, C. L., & Gendler, S. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100659 · Cited by 779
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Zhao, Z., Yang, Y., Zeng, Y., & He, M. (2016) · Lab on a Chip · doi:10.1039/c5lc01117e · Cited by 684
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Hensley, M., & Barakat, R. R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.051 · Cited by 634
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Kabawat, S. E., Bast, R. C., Bhan, A. K., Welch, W. R., Knapp, R. C., & Colvin, R. B. (1983) · International Journal of Gynecological Pathology · doi:10.1097/00004347-198303000-00005 · Cited by 588
Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N., & Ducarme, G. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0503-7 · Cited by 577
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Salani, R., Backes, F. J., Fung Kee Fung, M., Holschneider, C. H., Parker, L. P., Bristow, R. E., & Goff, B. A. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.008 · Cited by 428
Clarke-Pearson, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0901926 · Cited by 400
CA 125: The past and the Future
Bast, R. C., Xu, F.-J., Yu, Y.-H., Barnhill, S., Zhang, Z., & Mills, G. B. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300402 · Cited by 397
Potential markers that complement expression of CA125 in epithelial ovarian cancer
Rosen, D. G., Wang, L., Atkinson, J. N., Yu, Y., Lu, K. H., Diamandis, E. P., Hellstrom, I., Mok, S. C., Liu, J., & Bast, R. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.040 · Cited by 385
Can advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Self-citationJacobs, I., Davies, A. P., Bridges, J., Stabile, I., Fay, T., Lower, A., Grudzinskas, J. G., & Oram, D. (1993) · BMJ · doi:10.1136/bmj.306.6884.1030 · Cited by 360
Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., Timmerman, D., De Moor, B., & Vergote, I. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606092 · Cited by 354
Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018) · JAMA · doi:10.1001/jama.2017.21421 · Cited by 348
Ovarian Cancer: Etiology, Risk Factors, and Epidemiology
HUNN, J., & RODRIGUEZ, G. C. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31824b4611 · Cited by 324
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
The role of CA125 in clinical practice
Moss, E. L., Hollingworth, J., & Reynolds, T. M. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.018077 · Cited by 308
Cramer, D. W., Bast, R. C., Berg, C. D., Diamandis, E. P., Godwin, A. K., Hartge, P., Lokshin, A. E., Lu, K. H., McIntosh, M. W., Mor, G., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0195 · Cited by 300
Dennis, S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitão, M. M., Levine, D. A., Gardner, G. J., Abu‐Rustum, N. R., & Barakat, R. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.014 · Cited by 294
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 292
Nossov, V., Amneus, M., Su, F., Lang, J., Janco, J. M. T., Reddy, S. T., & Farias-Eisner, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.04.009 · Cited by 291
Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010602 · Cited by 283
A randomized study of screening for ovarian cancer: a multicenter study in Japan
KOBAYASHI, H., YAMADA, Y., SADO, T., SAKATA, M., YOSHIDA, S., KAWAGUCHI, R., KANAYAMA, S., SHIGETOMI, H., HARUTA, S., TSUJI, Y., et al. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01035.x · Cited by 276
Development of a Multimarker Assay for Early Detection of Ovarian Cancer
Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., Marks, J., Godwin, A., Gorelik, E., Jacobs, I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2484 · Cited by 274
CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma
Gu, P., Pan, L.-L., Wu, S.-Q., Sun, L., & Huang, G. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.02.019 · Cited by 265
Skates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
Horowitz, N. S., Miller, A., Rungruang, B., Richard, S. D., Rodriguez, N., Bookman, M. A., Hamilton, C. A., Krivak, T. C., & Maxwell, G. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3106 · Cited by 252
Pinsky, P., Miller, A., Kramer, B., Church, T., Reding, D., Prorok, P., Gelmann, E., Schoen, R., Buys, S., Hayes, R., et al. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk075 · Cited by 228
Suidan, R. S., Ramirez, P. T., Sarasohn, D. M., Teitcher, J. B., Mironov, S., Iyer, R. B., Zhou, Q., Iasonos, A., Paul, H., Hosaka, M., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.002 · Cited by 225
Makar, A. P., Baekelandt, M., Tropé, C. O., & Kristensen, G. B. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1027 · Cited by 219
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A., Felder, M., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 209
Cedrés, S., Nuñez, I., Longo, M., Martinez, P., Checa, E., Torrejón, D., & Felip, E. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.03.019 · Cited by 207
Kurman, R. J., Visvanathan, K., Roden, R., Wu, T. C., & Shih, I.-M. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.01.005 · Cited by 203
Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging
Javadi, S., Ganeshan, D. M., Qayyum, A., Iyer, R. B., & Bhosale, P. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15199 · Cited by 203
Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer
Cress, R. D., Chen, Y. S., Morris, C. R., Petersen, M., & Leiserowitz, G. S. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000981 · Cited by 201
Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels
Rustin, G. J. S., Marples, M., Nelstrop, A. E., Mahmoudi, M., & Meyer, T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4054 · Cited by 201
Ferraro, S., Braga, F., Lanzoni, M., Boracchi, P., Biganzoli, E. M., & Panteghini, M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201031 · Cited by 198
Jacobs, I. J., Skates, S., Davies, A. P., Woolas, R. P., Jeyerajah, A., Weidemann, P., Sibley, K., & Oram, D. H. (1996) · BMJ · doi:10.1136/bmj.313.7069.1355 · Cited by 197
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study
Anderson, G. L., McIntosh, M., Wu, L., Barnett, M., Goodman, G., Thorpe, J. D., Bergan, L., Thornquist, M. D., Scholler, N., Kim, N., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp438 · Cited by 197
Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4945 · Cited by 196
Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., Gohagan, J., Berg, C. D., & Prorok, P. C. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.334 · Cited by 191
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J., Rivkin, S., Schultes, B. C., Whiteside, T. L., & Nicodemus, C. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.016 · Cited by 191
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
Thériault, C., Pinard, M., Comamala, M., Migneault, M., Beaudin, J., Matte, I., Boivin, M., Piché, A., & Rancourt, C. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.020 · Cited by 189
Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant
Williams, R. M., Lee, C., Galassi, T. V., Harvey, J. D., Leicher, R., Sirenko, M., Dorso, M. A., Shah, J., Olvera, N., Dao, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aaq1090 · Cited by 183
Chekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 171
Benign conditions associated with raised serum CA-125 concentration
Buamah, P. K. (2000) · Journal of Surgical Oncology · Cited by 169
Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer
Marcus, C. S., Maxwell, G. L., Darcy, K. M., Hamilton, C. A., & McGuire, W. P. (2014) · Journal of Cancer · doi:10.7150/jca.7810 · Cited by 165
Santillan, A., Garg, R., ZAHURAK, M. L., Gardner, G. J., Giuntoli, R. L., Armstrong, D. K., & Bristow, R. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2582 · Cited by 163
Optimizing treatment in recurrent epithelial ovarian cancer
Corrado, G., Salutari, V., Palluzzi, E., Distefano, M. G., Scambia, G., & Ferrandina, G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1398088 · Cited by 160
Diagnostic accuracy of cancer antigen 125 for endometriosis: A systematic review and meta-analysis
Hirsch, M., Duffy, J., Davis, C., Nieves Plana, M., Khan, K., & on behalf of the International Collaboration to Harmonise Outcomes and Measures for Endometriosis (2016) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14055 · Cited by 156
Skates, S. J., Ankerst, D. P., & Jacobs, I. J. (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753168145 · Cited by 150
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van de Velde, N. M., Mourits, M. J. E., Arts, H. J. G., de Vries, J., Leegte, B. K., Dijkhuis, G., Oosterwijk, J. C., & de Bock, G. H. (2008) · International Journal of Cancer · doi:10.1002/ijc.24038 · Cited by 148
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
Andersen, M. R., Goff, B. A., Lowe, K. A., Scholler, N., Bergan, L. A., Drescher, C. W., Paley, P. J., & Urban, N. D. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.087 · Cited by 145
Sabbatini, P. J., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., Baumann, K., Kurzeder, C., Schmalfeldt, B., Cibula, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4057 · Cited by 145
Long-Term Survival of Women With Epithelial Ovarian Cancer Detected by Ultrasonographic Screening
van Nagell, J. R., Miller, R. W., DeSimone, C. P., Ueland, F. R., Podzielinski, I., Goodrich, S. T., Elder, J., Huang, B., Kryscio, R. J., & Pavlik, E. J. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318238d030 · Cited by 140
Subtypes of Ovarian Cancer and Ovarian Cancer Screening
Koshiyama, M., Matsumura, N., & Konishi, I. (2017) · Diagnostics · doi:10.3390/diagnostics7010012 · Cited by 137
Nustad, K., Bast, R. C., Brien, T. J. O. R., Nilsson, O., Seguin, P., Suresh, M. R., Saga, T., Nozawa, S., Børmer, O. P., de Bruijn, H. W. A., et al. (1996) · Tumor Biology · doi:10.1159/000217982 · Cited by 133
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer
Zhang, Z., Yu, Y., Xu, F., Berchuck, A., van Haaften‐Day, C., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Woolas, R. P., Jacobs, I. J., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.009 · Cited by 128
Factors influencing serum CA125II levels in healthy postmenopausal women.
Pauler, D. K., Menon, U., McIntosh, M. W., Symecko, H., Skates, S. J., & Jacobs, I. J. (2001) · PubMed · Cited by 124
Rosen, B. P., Laframboise, S., Ferguson, S. E., Dodge, J. E., Bernardini, M. Q., Murphy, J., Segev, Y., Sun, P., & Narod, S. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.004 · Cited by 119
Self-citationLiu, L., Xu, H., Wang, W.-Q., Wu, C., Xiang, J.-F., Liu, C., Long, J., Xu, J., Fu, D.-L., Ni, Q.-X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6819 · Cited by 119
Ovarian cancer: screening and future directions
Gupta, K. K., Gupta, V. K., & Naumann, R. W. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000016 · Cited by 115
STICS SCOUTs and p53 signatures a new language for pelvic serous carcinogenesis
Crum, C. P. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e275 · Cited by 111
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy
Das, S., & Batra, S. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1050 · Cited by 111
van Haaften‐Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Bast, R. C., & Hacker, N. F. (2001) · Cancer · Cited by 110
Karlsen, M. A., Høgdall, E. V. S., Christensen, I. J., Borgfeldt, C., Kalapotharakos, G., Dubská, L. Z., Chovanec, J., Lok, C. A. R., Stiekema, A., Mutz‐Dehbalaie, I., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.021 · Cited by 107
Riedinger, J., Wafflart, J., Ricolleau, G., Eche, N., Larbre, H., Basuyau, J. P., Dalifard, I., Hacène, K., & Pichon, M.-F. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl120 · Cited by 103
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
van der Burg, M. E. L., Lammes, F. B., & Verweij, J. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057754 · Cited by 103
Lloyd, K. O., Yin, B. W. T., & Kudryashov, V. (1997) · International Journal of Cancer · Cited by 102
CA 125 antigen in human amniotic fluid and fetal membranes
O’Brien, T. J., Hardin, J. W., Bannon, G. A., Norris, J. S., & Quirk, G. L. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90076-1 · Cited by 91
Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
Colombo, N., Lorusso, D., & Scollo, P. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001023 · Cited by 91
Smartphone-based immunosensor for CA125 detection
Hosu, O., Ravalli, A., Piccolo, G. M. L., Cristea, C., Săndulescu, R., & Marrazza, G. (2017) · Talanta · doi:10.1016/j.talanta.2017.01.073 · Cited by 90
Franier, B. D. L., & Thompson, M. E. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.03.041 · Cited by 90
Skates, S. J., Mai, P., Horick, N., PIEDMONTE, M. R., Drescher, C. W., Isaacs, C. J., Armstrong, D. K., Buys, S. S., Rodriguez, G. C., Horowitz, I., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0402 · Cited by 89
Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., & Cristofani, R. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1181 · Cited by 88
Somatic Mutaome Profile in Human Cancer Tissues
Kim, N., Hong, Y., Kwon, D., & Yoon, S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.239 · Cited by 87
Markman, M. M., Federico, M., Liu, P. Y., Hannigan, E. V., & Alberts, D. S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.02.024 · Cited by 87
The Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice
Kim, J., Coffey, D. M., Ma, L., & Matzuk, M. M. (2015) · Endocrinology · doi:10.1210/en.2014-1977 · Cited by 85
Matsuoka, Y., Endo, K., Kawamura, Y., Yoshida, T., Saga, T., Watanabe, Y., Koizumi, M., Nakashima, T., Konishi, J., Yamaguchi, N., et al. (1990) · Cancer · Cited by 85
The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass
Chan, K. K. L., Chen, C., Nam, J., Ochiai, K., Wilailak, S., Choon, A. T., Sabaratnam, S., Hebbar, S., Sickan, J., Schodin, B. A., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.034 · Cited by 85
Kristjánsdóttir, B., Levan, K., Partheen, K., & Sundfeldt, K. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.094 · Cited by 83
Surveillance of patients after initial treatment of ovarian cancer
Gadducci, A., & Cosio, S. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.12.008 · Cited by 81
Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer
Amonkar, S. D., Bertenshaw, G. P., Chen, T., Bergstrom, K. J., Zhao, J., Seshaiah, P., Yip, P. F., & Mansfield, B. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004599 · Cited by 75
The tumor marker CA 125 is a common constituent of normal cervical mucus
de Bruijn, H. W. A., Calkoen-Carpay, T. V. B., Jager, S., Duk, J. M., Aalders, J. G., & Fleuren, G. J. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90757-x · Cited by 75
Drescher, C. W., Shah, C., Thorpe, J. D., O'Briant, K. C., Anderson, G. L., Berg, C. D., Urban, N. D., & McIntosh, M. W. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6691 · Cited by 75
CA 125 and the detection of recurrent ovarian cancer
Bast, R. C. (2010) · Cancer · doi:10.1002/cncr.25203 · Cited by 73
Enakpene, C. A., Omigbodun, A. O., Goecke, T. W., Odukogbe, A. T. A., & Beckmann, M. W. (2008) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2008.00869.x · Cited by 65
Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses
Chen, X., Zhou, H., Chen, R., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.013 · Cited by 62
Szubert, M., Suzin, J., Wierzbowski, T., & Amico, K. R. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.29529 · Cited by 62
Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer
Akinwunmi, B. O., Babić, A., Vitonis, A. F., Cramer, D. W., Titus, L. J., Tworoger, S. S., & Terry, K. L. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0203 · Cited by 62
Comparison of candidate serologic markers for type I and type II ovarian cancer
Lü, D., Kuhn, E., Bristow, R. E., Giuntoli, R. L., Kjær, S. K., Shih, I., & Roden, R. B. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.039 · Cited by 60
Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16
Rao, T. D., Park, K. J., Smith-Jones, P. M., Iasonos, A. E., Linkov, I., Soslow, R. A., & Spriggs, D. R. (2010) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181dbfcd2 · Cited by 58
Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifyingGolgi/post-Golgi compartments
Das, S., Majhi, P. D., Al‐Mugotir, M., Rachagani, S., Sorgen, P. L., & Batra, S. K. (2015) · Scientific Reports · doi:10.1038/srep09759 · Cited by 56
Fleming, N. D., Cass, I. A., Walsh, C., Karlan, B. Y., & Li, A. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.014 · Cited by 54
Integrated Microfluidic Lectin Barcode Platform for High-Performance Focused Glycomic Profiling
Shang, Y., Zeng, Y., & Zeng, Y. (2016) · Scientific Reports · doi:10.1038/srep20297 · Cited by 52
Musalhi, K. A., Kindi, M. A., Aisary, F. A., et al. (2016) · Oman Medical Journal · doi:10.5001/omj.2016.68 · Cited by 52
Diagnostic value of HE4 for ovarian cancer: a meta-analysis
Yu, S., Yang, H.-J., Xie, S., et al. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0477 · Cited by 50
Blyuss, O. B., Burnell, M., Ryan, A., Gentry‐Maharaj, A., Mariño, I. P., Kalsi, J., Manchanda, R., Timms, J. F., Parmar, M., Skates, S. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0208 · Cited by 50
Pinsky, P. F., Zhu, C. S., Skates, S., Black, A., Partridge, E. E., Buys, S. S., & Berg, C. D. (2012) · International Journal of Cancer · doi:10.1002/ijc.27909 · Cited by 49
Gedi, V., Song, C. K., Kim, G. B., Lee, J. O., Oh, E., Shin, B. S., Jung, M., Shim, J., Lee, H., & Kim, Y. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.10.049 · Cited by 49
Why have ovarian cancer mortality rates declined? Part III. Prospects for the future
Sopik, V., Rosen, B. P., Giannakeas, V., & Narod, S. A. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.019 · Cited by 47
Self-citationPrognostic value of CA125 in advanced heart failure patients
Monteiro, S. R., Franco, F., Costa, S., Monteiro, P. F., Vieira, H. D., Coelho, L., Oliveira, L., & Providência, L. A. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.023 · Cited by 46
Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm
Harðardóttir, H., Parmley, T. H., Quirk, J. G., Sanders, M. M., Miller, F. C., & O’Brien, T. J. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90775-3 · Cited by 45
CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
Chen, X., Zhang, J., Cheng, W., Chang, D. Y., Huang, J., Wang, X., Jia, L., Rosen, D. G., Zhang, W., Yang, D., et al. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31828f7a24 · Cited by 45
CALSTER, B. V., Valentin, L., Holsbeke, C. V., Zhang, J., Jurkovic, D., Lissoni, A. A., Testa, A. C., Czekierdowski, A., Fischerová, D., Domali, E., et al. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0422 · Cited by 41
Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review
Kumari, S. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0786-2 · Cited by 40
Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
Russell, M. R., Graham, C., D’Amato, A., Gentry‐Maharaj, A., Ryan, A., Kalsi, J., Whetton, A. D., Menon, U., Jacobs, I. J., & Graham, R. L. J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0544-0 · Cited by 36
Xu, Y. X., Zhong, R., He, J., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.07.029 · Cited by 35
Wang, F., Ye, Y., Xu, X., Zhou, X., Wang, J., & Chen, X. (2013) · Journal of Ovarian Research · doi:10.1186/1757-2215-6-14 · Cited by 31
Leandersson, P., Kalapotharakos, G., Hénic, E., Borgfeldt, H., Petzold, M., Høyer‐Hansen, G., & Borgfeldt, C. (2016) · PubMed · Cited by 28
Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
Zhang, H., Yang, Y.-A., Wang, Y., Gao, X., Wang, W., Liu, H., He, H., Liang, Y., Pan, K., Wu, H., et al. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0132-8 · Cited by 27
Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value
Bonfrèr, J. M. G., Korse, C. M., Verstraeten, R. A., van Kamp, G. J., Hart, G. A. M., & Kenemans, P. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.3.491 · Cited by 25
Temkin, S. M., Miller, E. A., Samimi, G., Berg, C. D., Pinsky, P. F., & Minasian, L. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.015 · Cited by 25
Use of CA‐125 response to predict survival parameters of patients with advanced ovarian carcinoma
Ron, I., Inbar, M., Gelernter, I., Lewysohn, O., Ayalon, D., Dale, J., & Chaitchik, S. (1994) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349409013462 · Cited by 24
Clinical Value of a New Serum Tumor Marker, CA125 II, in Gynecologic Disease: Comparison with CA125
Tamakoshi, K., Kikkawa, F., Hasegawa, N., et al. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000292393 · Cited by 22
Morshed, G., & Fathy, S. M. (2015) · Videosurgery and Other Miniinvasive Techniques · doi:10.5114/wiitm.2015.56480 · Cited by 17
Cancer antigen 125 after delivery in women with a normal pregnancy: a prospective cohort study
Szecsi, P. B., Andersen, M. R., Bjørngaard, B., Hedengran, K. K., & Stender, S. (2014) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12492 · Cited by 16
Grønlund, B., Dehn, H., Høgdall, C. K., Engelholm, S. A., JORGENSEN, M., Nørgaard‐Pedersen, B., & Høgdall, E. V. S. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00145.x · Cited by 12
Seong, W. J. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3775-1 · Cited by 10
Yanaranop, M., Jantarateptewan, N., Tiyayon, J., et al. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001277 · Cited by 8
Cited by
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Liquid biopsies: the future of cancer early detection
Connal, S., Cameron, J. M., Sala, A., Brennan, P. M., Palmer, D. S., Palmer, J. D., Perlow, H., & Baker, M. J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03960-8 · Cited by 370
A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing
Wang, C.-W., Weaver, S. D., Boonpattrawong, N., Schuster-Little, N., Patankar, M., & Whelan, R. J. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0327 · Cited by 12
Metadata
- Authors
- Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-12-11
- Volume
- 12
- Issue
- 12
- Pages
- 3730
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3111315732
- Cited by
- 602
- References
- 146
- FWCI
- 33.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.